How much does a box of Vebreltinib cost? Price introduction

Vebreltinib/vebreltinib has been independently developed and marketed in China and is included in the scope of medical insurance, providing an accessible targeted treatment option for some patients with malignant tumors. Its main indications include non-small cell lung cancer (NSCLC) and brain glioma. InNSCLC, bricitinib is specifically targeted to patients with locally advanced or metastatic disease who have mesenchymal-to-epithelial transition factor (MET) exon 14 skipping. MET exon 14 skipping can lead to abnormal expression of MET protein and promote the proliferation and metastasis of tumor cells. By inhibiting the MET signaling pathway, bricitinib helps delay disease progression and improve treatment response rate.

In terms of brain glioma, boricitinib is suitable for patients with IDH mutant astrocytoma who have failed previous treatment and have thePTPRZ1-MET fusion gene, as well as some adult patients with low-grade glioblastoma. As treatment options for brain glioma are limited, the launch of bricitinib provides these patients with a new precision treatment option. Genetic testing is usually required before drug use to determine MET exon 14 skipping or PTPRZ1-MET fusion gene status, so as to achieve personalized and precise medication.

The specification of Bricitinib is100mg*60 tablets, and each box sells for about 7,000 yuan. Since the drug has been included in medical insurance, eligible patients can reduce financial pressure through medical insurance reimbursement in the hospital. Currently, there are no generic drugs in China, and patients can only purchase original drugs through regular hospitals or authorized pharmacies. In clinical use, doctors will develop an individualized medication plan based on the patient's genetic test results, disease classification and weight, and coordinate with regular imaging and biomarker monitoring to ensure maximum drug safety and efficacy.

In general, boricitinib is not only an innovative targeted anti-cancer drug, but its medical insurance coverage and domestic independent production have also significantly improved patient accessibility, providing a precise, efficient and sustainable treatment option for lung cancer and glioma patients with abnormal MET pathways. It also represents the forefront of domestic targeted drug development and application.

Reference materials:https://www.asymbio.com.cn/